3.4.22.26: cancer procoagulant
This is an abbreviated version!
For detailed information about cancer procoagulant, go to the full flat file.
Word Map on EC 3.4.22.26
-
3.4.22.26
-
coagulation
-
proteinase
-
thromboembolic
-
clot
-
thrombosis
-
intravascular
-
gordon
-
amnion-chorion
-
hypercoagulability
-
thrombin-antithrombin
-
thrombogenic
-
three-stage
-
prothrombotic
-
warfarin
-
benson
-
anti-cp
-
k-dependent
-
haemostatic
-
x-activating
-
medicine
- 3.4.22.26
- coagulation
- proteinase
-
thromboembolic
- clot
- thrombosis
-
intravascular
-
gordon
-
amnion-chorion
- hypercoagulability
-
thrombin-antithrombin
-
thrombogenic
-
three-stage
-
prothrombotic
- warfarin
-
benson
-
anti-cp
-
k-dependent
-
haemostatic
-
x-activating
- medicine
Reaction
specific cleavage of Arg-/-Ile bond in Factor X to form Factor Xa =
Synonyms
cancer procoagulant, CP
ECTree
Advanced search results
Inhibitors
Inhibitors on EC 3.4.22.26 - cancer procoagulant
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
-
enhanced in reduced environment
trans-epoxysuccinyl-L-leucyl-amido(4-guanidino)butane
-
i.e. E-64, thiol protease inhibitor, factor X protects
trans-epoxysuccinyl-L-leucyl-amido(4-guanidino)butane
-
enhanced in reduced environment
-
i.e. E-64, reversible, competitive
trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane
-
ie.e. E-64, reversible, competitive
additional information
-
no inhibition by alpha2-macroglobulin, alpha1-antiprotease, antithrombin III/heparin, cystatin, cysteamine, alpha1-anichymotrypsin, the effectiveness of most of the inhibitors increase in presence of reducing agents
-